Navigating Import & Export Controls for Pharmaceuticals in Asia

Asia is the world’s fastest-growing pharmaceutical market — and simultaneously one of its most complex regulatory environments. Getting a product across a border in this region is not a logistics challenge. It is a regulatory, documentary, and strategic one.

Moving pharmaceuticals across Asian borders has never been more commercially important, or more technically demanding. The Asia-Pacific pharmaceutical market was valued at USD 421 billion in 2024 and is projected to reach USD 583 billion by 2029 — a compound annual growth rate of 6.7% that outpaces every other major regional market globally. The pipeline of biologics, advanced therapy medicinal products, and specialty medicines flowing into and across the region is expanding rapidly.

But the regulatory infrastructure governing pharmaceutical import and export controls in Asia is not a single framework. It is a patchwork of national systems — each with its own licensing requirements, documentation standards, inspection regimes, and enforcement priorities — that vary significantly from market to market and change with a frequency that consistently catches companies off guard.

Understanding how pharmaceutical import and export controls work across Asia’s key markets, where the friction points cluster, and what best practice looks like in practice is not optional for any company with regional ambitions. It is the foundation on which market access strategy is built.

🌏 The Regulatory Landscape: Fragmented by Design

Unlike the European Union — where the EMA provides a centralised marketing authorisation pathway and GDP guidelines apply consistently across member states — Asia has no equivalent supranational regulatory authority. Each market operates its own pharmaceutical regulatory system, and the divergence between them is substantial.

The region’s principal regulatory authorities and their governing frameworks include:

This fragmentation has direct operational consequences. A pharmaceutical company exporting a single product to five Asian markets may need to manage five separate import licence applications, five different documentation packages, five distinct labelling requirements, and five regulatory timelines — none of which are synchronised.

A 2024 survey by the Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum found that regulatory divergence across Asian markets added an average of 14.3 months to pharmaceutical market entry timelines compared to equivalent EU market entry processes — and that documentation inconsistencies were the single most frequently cited cause of import clearance delays.

📋 Import Controls: What the Paperwork Actually Requires

Pharmaceutical import controls across Asia share a common structural logic — import licences, product registration, and shipment-level documentation — but the specific requirements within each category vary considerably between markets.

Product Registration as a Prerequisite for Import

In virtually every Asian market, a pharmaceutical product must be registered with the national regulatory authority before it can be legally imported. Registration is not a customs formality. It is a full regulatory review process — evaluating quality, safety, and efficacy data — that can take anywhere from six months in Singapore to three to five years in Indonesia for a standard new chemical entity.

The registration timelines across key Asian markets illustrate the scale of the planning challenge:

• Singapore (HSA): 12–18 months for full review; expedited pathways available for products with prior approval from reference agencies (EMA, TGA, Health Canada)
• Japan (PMDA): 12 months standard; priority review designation available for unmet medical needs
• South Korea (MFDS): 18–24 months; local clinical data requirements apply for certain product categories
• China (NMPA): 12–36 months depending on product category; domestic clinical trial requirements significantly extended timelines prior to 2017 reforms, with ongoing evolution
• India (CDSCO): 12–24 months; local clinical trial waiver available for products approved in specified reference countries
• Indonesia (BPOM): 24–60 months; one of the longest registration timelines in the region, with significant backlog challenges documented by the APEC LSIF
• Vietnam (DAV): 18–36 months; registration renewal requirements add ongoing compliance burden
• Thailand (Thai FDA): 12–24 months; GMP certificate from country of manufacture required

The practical implication is that pharmaceutical import and export planning in Asia must begin years before the intended commercial launch date — and that registration strategy must be sequenced carefully to align with commercial priorities and available regulatory resources.

Import Licence Requirements

Beyond product registration, most Asian markets require a separate import licence or import permit for each shipment or category of shipments. The structure of these requirements varies:

China requires an Import Drug Licence (進口藥品注冊證) as the primary registration document, supplemented by a Customs Declaration and a Drug Inspection Report issued by a NMPA-designated inspection agency for each imported batch. Since the 2019 Drug Administration Law revision, the requirement for batch-by-batch inspection has been modified for certain product categories — but the documentation burden remains substantial.

Japan requires an import business licence (輸入業許可) held by the importer, in addition to the marketing authorisation. Foreign manufacturers must also hold a Foreign Manufacturer Accreditation (外国製造業者認定) issued by PMDA. The combination of these requirements means that the Japanese import control system effectively requires regulatory engagement at both the manufacturer and importer level simultaneously.

India requires a No Objection Certificate (NOC) from CDSCO for import of pharmaceutical products not yet registered in India — a requirement that creates a parallel documentation pathway for clinical trial materials, reference standards, and investigational medicinal products that is frequently underestimated in complexity.

Indonesia requires a Special Import Licence (Surat Persetujuan Impor — SPI) for each import consignment of registered pharmaceutical products, issued by the Ministry of Trade on the basis of BPOM recommendation. The dual-ministry involvement in Indonesian pharmaceutical import controls is a distinctive feature of the system that adds procedural complexity not present in most other Asian markets.

Labelling and Language Requirements

Labelling requirements for imported pharmaceuticals in Asia are among the most operationally demanding elements of import control compliance. Most Asian markets require that product labels include local language text — and in several markets, local language labelling must be applied before customs clearance, not after.

China requires Mandarin labelling on all imported pharmaceutical products, with the Chinese label required to match the approved registration dossier exactly. Any deviation — including font size, layout, or content — constitutes a labelling violation that can result in customs detention or product recall.

South Korea requires Korean language labelling, with specific requirements for font size, mandatory label elements, and the placement of the Korean importer’s details.

Thailand requires Thai language labelling for all pharmaceutical products sold in the Thai market, with the Thai FDA requiring label approval as part of the registration process.

A 2023 analysis of pharmaceutical import clearance delays across Southeast Asian markets found that labelling non-compliance was the cause of 28% of all customs detention incidents — making it the second most common cause of import delay after incomplete documentation.

🚢 Export Controls: The Overlooked Dimension

While import controls receive the majority of regulatory attention, export controls for pharmaceuticals in Asia are an increasingly significant compliance consideration — particularly for manufacturers based in India, China, and South Korea who are major exporters of active pharmaceutical ingredients (APIs) and finished dosage forms to global markets.

India: The World’s Pharmacy and Its Export Compliance Framework

India is the world’s largest exporter of generic pharmaceuticals by volume, supplying approximately 20% of global generic medicine exports by volume and providing over 60% of the WHO’s vaccine requirements. The export compliance framework governing this output is administered by CDSCO in conjunction with the Directorate General of Foreign Trade (DGFT).

Key export control requirements for pharmaceutical exports from India include:

• Schedule H and Schedule X controlled substances require specific export authorisation from CDSCO, with documentation requirements aligned to the International Narcotics Control Board (INCB) reporting framework
• API exports are subject to export licensing requirements under the Foreign Trade Policy, with certain APIs — particularly those identified as critical during the COVID-19 pandemic — subject to export restriction or quota controls that have been maintained in modified form since 2020
• GMP certification from CDSCO is required for export of pharmaceutical products, with the certificate of pharmaceutical product (CPP) issued under the WHO certification scheme required by most importing country regulatory authorities

A 2024 DGFT analysis found that pharmaceutical exports from India reached USD 27.9 billion in FY2023-24 — a 9.7% increase year-on-year — with regulatory documentation compliance identified as the primary bottleneck in export processing time.

China: NMPA Export Controls and the Certificate of Free Sale

China’s pharmaceutical export control framework has undergone significant reform since the 2019 Drug Administration Law revision. Pharmaceutical manufacturers exporting from China must hold a valid Drug Manufacturing Licence and, for exports to regulated markets, must demonstrate GMP compliance through NMPA inspection.

The Certificate of Free Sale (CFS) — required by most Asian importing country authorities as evidence that the product is legally marketed in the country of manufacture — is issued by NMPA and has become a critical document in China’s pharmaceutical export documentation package. Processing times for CFS issuance from NMPA averaged 45–60 working days in 2024, a timeline that requires careful integration into export planning schedules.

⚠️ The High-Risk Categories: Controlled Substances, Biologics, and Cold Chain Products

Three product categories consistently generate the highest volume of import and export control complications across Asian markets.

Controlled substances — narcotics, psychotropics, and precursor chemicals — are subject to import and export authorisation requirements under both national legislation and the UN drug control conventions in every Asian market. The documentation requirements are extensive, the processing timelines are long, and the consequences of non-compliance are severe. A 2023 INCB report noted that documentation errors in controlled substance import/export authorisations accounted for 31% of all reported compliance incidents in the Asia-Pacific region.

Biological products — including vaccines, monoclonal antibodies, and cell and gene therapy products — face additional import control requirements in most Asian markets, including batch release testing by national control laboratories, cold chain documentation requirements, and in some markets, mandatory local stability studies. Japan’s PMDA, South Korea’s MFDS, and China’s NMPA all maintain specific biological product import control frameworks that are distinct from those governing small molecule pharmaceuticals.

Cold chain products face the intersection of pharmaceutical import controls and temperature-sensitive logistics requirements — with documentation requirements for temperature monitoring during transit increasingly embedded in import control frameworks. China’s NMPA, for example, requires temperature records covering the complete transit from manufacturer to Chinese port of entry as part of the import inspection documentation package.

💡 Building a Compliant Import and Export Strategy for Asia

The organisations that navigate pharmaceutical import and export controls in Asia most effectively share a consistent set of strategic and operational characteristics.

They invest in local regulatory intelligence. Regulatory requirements across Asian markets change frequently — and the changes are not always well-publicised in English. Organisations with in-market regulatory affairs capability, or with established relationships with local regulatory consultants, consistently identify and respond to regulatory changes faster than those relying solely on global regulatory intelligence services.

They build documentation management systems that scale. The volume of documentation required to support pharmaceutical import and export across multiple Asian markets simultaneously is substantial. Organisations that manage this through structured document management systems — with version control, expiry tracking, and market-specific documentation templates — consistently experience fewer clearance delays than those managing documentation through unstructured processes.

They plan registration timelines against commercial timelines. The single most common strategic error in Asian pharmaceutical market entry is underestimating registration timelines and their impact on commercial launch dates. Effective import and export strategy begins with a realistic assessment of registration timelines in each target market and works backwards to identify the latest possible date for registration submission.

They treat third-party logistics providers as regulatory partners. Import clearance in Asia is not solely a regulatory affairs function. Freight forwarders, customs brokers, and third-party logistics providers play critical roles in import documentation preparation and customs clearance — and their GDP compliance, regulatory knowledge, and documentation capabilities directly affect import clearance outcomes.

The Asia-Pacific pharmaceutical market’s growth trajectory makes it one of the most important strategic priorities for pharmaceutical companies globally. But market access in Asia is earned through regulatory competence, not commercial ambition. The import and export control frameworks that govern pharmaceutical movement across the region are complex, fragmented, and unforgiving of preparation gaps.

The companies that succeed are those that treat regulatory compliance not as a barrier to market entry, but as the foundation on which sustainable market access is built.